Yong et al. methodically evaluated the role of the long noncoding RNA (lncRNA) DLEU2/miR-529-3p/HOXB2
axis in Wilm's tumor pathogenesis [
[1]
]. Through a set of nicely designed experimental studies, the investigators examined
the expression of the novel lncRNA DLEU2 in primary Wilm's tumor tissue, Wilm's tumor
cell lines, and a xenograft model, and evaluated its regulation by the microRNA miR-539-3p
and involvement in expression of the oncogene HOXB2. While previously found to have
relevance in other malignancies, this is the first comprehensive evaluation of the
expression of these nucleotides with Wilm's tumor progression. DLEU2 impacted cell
viability, proliferation, and cell migration in Wilm's tumor cell lines. Through silencing
mechanisms, the investigators identified miR-539-3P as a downstream target inhibiting
DLEUC2 expression; and that HOXB2, regulated by miR-539-3P, was able to restore the
tumorigenic potential of DLEU2. The execution of their studies, use of multiple modalities,
and straightforward methodology make this paper easy to follow and accessible to a
wide reader audience. The science and results are compelling. It is a nice example
of signaling pathway analysis and certainly supports the potential role for targeting
lncRNAs, like DLEU2, in the pathogenesis of Wilm's tumors.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Pediatric UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Long noncoding RNA DLEU2 regulates the progression of Wilm's tumor via miR-539-3p/HOXB2 axis.J Pediatr Urol. 2022; (In press)
- Noncoding RNA therapeutics – challenges and potential solutions.Nat Rev Drug Discov. 2021; 20: 629-651
- From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA Type 1.Pediatr Neurol. 2019; 100: 3-11
- Lumasiran: first approval.Drugs. 2021; 81: 277-282
Article info
Publication history
Published online: September 23, 2022
Accepted:
August 7,
2022
Received:
July 29,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Long noncoding RNA DLEU2 regulates the progression of Wilm's tumor via miR-539-3p/HOXB2 axisJournal of Pediatric Urology
